Trending...
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic® in Ocudose®) and has begun commercialization activities.
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:
"We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio," stated Daniel Carbery, President and CEO of Amring. "We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines."
More on The PennZone
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
More on The PennZone
Contacts
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:
- the preservative in Timolol Maleate Ophthalmic Solution, USP,
- benzalkonium chloride, or
- when the use of a preservative-free topical medication is advisable.
"We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio," stated Daniel Carbery, President and CEO of Amring. "We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines."
More on The PennZone
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
- TrueNorth Wellness Services Expands Rural Behavioral Health Care in Fulton County with Technology
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
More on The PennZone
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
- Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
- P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
- Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
Contacts
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com
0 Comments
Latest on The PennZone
- UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
- ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
- NAO Releases Shopping Intelligence to Streamline Your Quest for Value
- International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
- The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
- CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
- RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
- Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- MoMojo Records Signs Gary Nicholson
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
- Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)